The association between congestive heart failure and chronic renal disease

Current Opinion in Nephrology and Hypertension

Volumn 13, Issue 2, 2004, Pages 163-170

  Silverberg, Donald ^a   Wexler, Dov ^a   Blum, Miriam ^a   Schwartz, Doron ^a   Iaina, Adrian ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Anemia; Erythropoietin; Heart failure; Progression of renal disease; Renal failure

Indexed keywords

CARVEDILOL; NONSTEROID ANTIINFLAMMATORY AGENT; SIMVASTATIN;

ANEMIA; CHRONIC KIDNEY DISEASE; CONGESTIVE HEART FAILURE; DIALYSIS; DISEASE ASSOCIATION; EXERCISE; HEART PROTECTION; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; MALNUTRITION; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW;

ANEMIA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHRONIC DISEASE; HEART FAILURE, CONGESTIVE; HUMANS; KIDNEY DISEASES; NATRIURETIC PEPTIDE, BRAIN; RECEPTORS, ANGIOTENSIN; UREMIA;

EID: 1642268312     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-200403000-00004     Document Type: Review

References (70)

1. Miller LW, Missov ED. Epidemiology of heart failure. Cardiol Clin 2001; 4:547-555.
2. Jessup M, Brozena S. Heart failure. N Engl J Med 2003; 348:2007-2018. This is a practical, up-to-date summary of the treatment of heart failure.
3. Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002; 347:1397-1402.
4. Cleland JG, Cohen-Solal A, Aguillar JC, et al. Management of heart failure in primary care (The IMPROVEMENT of heart failure programme): an international survey. Lancet 2002; 360:1631-1639.
5. Silverberg DS, Wexler D, Blum M, Iaina A. The cardio renal anemia syndrome: correcting anemia in patients with resistant congestive heart failure can improve both the cardiac and renal function and reduce hospitalizations. Clin Nephrol 2003; 60 (Suppl 1):S93-S102. This is a review of the relationship between heart failure and anemia and the effects on CHF and CKD of correction of the anemia.
6. Laskar SR, Dries DL. The prognostic significance of renal dysfunction in patients with chronic systolic heart failure. Curr Cardiol Rep 2003; 5:205-210. This is a review of the mechanism of renal failure in heart failure, and the effect of renal failure on cardiovascular complications.
7. Shlipak MG. Pharmacotherapy for heart failure in patients with renal insufficiency. Ann Intern Med 2003; 138:917-924. This is a review of the efficacy and dangers of cardiovascular drugs in heart failure patients with renal failure.
8. Schreiber BD. Congestive heart failure in patients with chronic kidney disease and on dialysis. Am J Med Sci 2003; 325:179-193. This gives a detailed analysis of the factors contributing to CHF in patients on dialysis, and of the effects of intervention.
9. Ritz E, Dikow R, Adamzcak M, Zeier M. Congestive heart failure due to systolic dysfunction: the Cinderella of cardiovascular management in dialysis patients. Semin Dial 2002; 15:135-140.
10. Silverberg DS, Wexler D, Blum M, et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function, functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 2000; 35:1737-1744.
11. McClellan WM, Flanders WD, Langston RD, et al. Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study. J Am Soc Nephrol 2002; 13:1928-1936.
12. Hillege HL, Girbes ARJ, de Kam PJ, et al. Renal function, neurohormonal activation and survival in patients with chronic heart failure. Circulation 2000; 102:203-210.
13. Obrador GT, Pereira BJG, Kausz AT. Chronic kidney disease in the United States. Semin Nephrol 2002; 22:441-448.
14. Klarenbach S, Stafinski T, Longobardi T, Jacobs P. The effect of renal insufficiency on workforce participation in the United States: an analysis using National Health and Nutrition Examination Survey III data. Am J Kidney Dis 2002; 40:1132-1137.
15. Avorn J, Bohn RL, Levy E, et al. Nephrologist care and mortality in patients with chronic renal insufficiency. Arch Intern Med 2002; 162:2002-2006.
16. Collins AJ. Cardiovascular mortality in end-stage renal disease. Am J Med Sci 2003; 325:163-167.
17. Horl WH, MacDougall IC, Rossert J, et al. Predialysis survey on anemia management: patient referral. Am J Kidney Dis 2003; 421:49-61.
18. Silverberg DS, Wexler D, Blum M, et al. Aggressive therapy of congestive heart failure and associated chronic renal failure with medications and correction of anemia stops or slows the progression of both diseases. Perit Dial Int 2001; 21 (Suppl 3):S236-S240.
19. Silverberg DS, Wexler D, Blum M, et al. The effect of correction of anemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutanous erythropoietin and intravenous iron. Nephrol Dial Transplant 2003; 18:141-146.
20. Van Dokkum RPE, Henning RW, Kluppel ACA, et al. Myocardial infarction aggravates chronic renal function loss: a rat model of cardiorenal interaction. J Am Soc Nephrol 2002; 13 (Suppl): 558A (Abstract).
21. Gilbertson D, Li S, Murray AM, et al. Competing risks of death vs ESRD in Medicare beneficiaries age 65+ with chronic kidney disease, CHF, and anemia. J Am Soc Nephrol 2002; 13 (Suppl): 439A (Abstract).
22. Perry HM, Miller JO, Fornoff JR, et al. Early predictors of 15 year end-stage renal disease in hypertensive patients. Hypertension 1995; 25:587-594.
23. Hillege HL, van Gilst WH, van Veldhuisen DJ, et al. Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: the CATS randomized trial. Eur Heart J 2003; 24:412-420. This is one of the few studies to explore the relationship between CHF and progressive decline in renal function.
24. Hillege HL, van Gilst W, Kingma J, et al. Myocardial infarction is associated with renal function loss which is counteracted by ACE inhibition. J Am Soc Nephrol 1999; 10 (Supplement): 384A (Abstract).
25. Silverberg DS, Wexler D, Sheps D, et al. The effect of correction of mild anemia in severe resistant heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled trial. J Am Coll Cardiol 2001; 37:1775-1880.
26. Knight EL, Glynn RJ, McIntyre KM, et al. Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD). Am Heart J 1999; 138:849-855.
27. Levin A, Djurdjev O, Barrett B, et al. Cardiovascular disease in patients with chronic kidney disease: getting to the heart of the matter. Am J Kidney Dis 2001; 38:1398-1407.
28. Deicher R, Horl WH. Anaemia as a risk factor for the progression of chronic kidney disease. Curr Opin Nephrol Hypertens 2003; 12:139-144.
29. Fine L, Dandyopadhay D, Norman JT. Is there a common mechanism for the progression of different types of renal diseases other than proteinuria? Towards the unifying theme of chronic hypoxia. Kidney Int 2000; 57 (Suppl 75):S22-S26.
30. Yu HT. Progression of chronic renal failure. Arch Intern Med 2003; 163:1417-1429. This is an extensive review of the factors causing progressive renal failure and the effects of different kinds of intervention.
31. Yoshida H, Yashiro M, Liang P, et al. Mesangiolytic glomerulopathy in severe congestive heart failure. Kidney Int 1998; 53:880-691.
32. Dries DL, Exner DV, Domanski MJ, et al. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2000; 35:681-689.
33. Amann K, Ritz C, Adamczak M, Ritz E. Why is coronary heart disease of uraemic patients so frequent and so devastating? Nephrol Dial Transplant 2003; 18:631-640.
34. Mann JFE, Gerstein HC, Dulau-Florea I, Lonn E. Cardiovascular risk in patients with mild renal insufficiency. Kidney Int 2003; 63 (Suppl 84):S192-S196.
35. Zoccali C, Mallamaci F, Tripepi G. Traditional and emerging cardiovascular risk factors in end-stage renal disease. Kidney Int 2003; 63 (Suppl 85):S105-S110.
36. Stenvinkel P, Pecoits-Filho R, Lindholm B. Coronary artery disease in end-stage renal disease: no longer a simple plumbing question. J Am Soc Nephrol 2003; 14:1927-1939.
37. Tyralla K, Amann K. Morphology of the heart and arteries in renal failure. Kidney Int 2003; 84 (Suppl 84):S80-S83.
38. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348:1309-1321.
39. Node K, Fujita M, Kitakaze M, et al. Short-term statin therapy improves cardiac function and symptoms in patients with dilated cardiomyopathy. Circulation 2003; 108:839-843. Epub 2003, Jul. 28. Erratum: Circulation 2003; 108:2170.
40. Foley RN, Herzog CA, Collins AJ. Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study. Kidney Int 2002; 62:1784-1790.
41. Trespalacios FC, Taylor AJ, Agodoa LY, Abbott KC. Incident acute coronary syndromes in chronic dialysis patients in the United States. Kidney Int 2002; 62:1799-1805.
42. Berl T, Hunsicker LG, Lewis JB, et al. Cardiovascular outcomes in the Irbestan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Int Med 2003; 138:542-549.
43. Brenner BM, Cooper ME, De Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869.
44. The CONSENSUS Trial study group; effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316:1429-1435.
45. Erdmann E, Lechat P, Verkenne P, et al. Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol on high-risk patient groups with chronic heart failure. Eur J Heart Fail 2001; 3:469-479.
46. Cice G, Ferrara L, D'Andrea A, et al. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy. J Am Coll Cardiol 2003; 41:448-444. This is a controlled study of the effects of beta blockers in dilated cardiomyopathy in hemodialysis patients.
47. The Seventh Report of the Joint National Committee on the Prevention, Detection and Treatment of High Blood Pressure. JAMA 2003; 289:2560-2572. This is a summary of all aspects of hypertension, and includes sections on associated renal failure and heart failure.
48. Tonelli M, Bohm C, Pandeya S. Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency. Am J Kidney Dis 2001; 37:484-489.
49. Trespalacios FC, Taylor AJ, Agodoa LY, et al. Heart failure as a cause of hospitalization for chronic dialysis patients. Am J Kidney Dis 2003; 41:1267-1277.
50. Stafford RS, Radley DC. The underutilization of cardiac medications of proven benefit, 1990-2002. J Am Coll Cardiol 2003; 41:56-61.
51. Maggioni AP, Sinagra G, Opasich C, et al. Treatment of chronic heart failure with B adrenergic blockade beyond controlled clinical trials: the BRING-UP experience. Heart 2003; 89:299-305.
52. Iverson PO, Wolbaek PR, Tonnessen T, Christensen G. Decreased hematopoeisis in bone marrow of mice with congestive heart failure. Am J Physiol 2002; 282:R166-R172.
53. Horwich TB, Fonarow GC, Hamilton MA, et al. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol 2002; 39:1780-1786.
54. Al-Ahmad A, Rand WM, Manjunath G, et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 2001; 8:955-962.
55. Valderabano F, Horl W, Macdougall IC, et al. PRE-dialysis survey on anemia management. Nephrol Dial Transplant 2003; 18:89-100.
56. St Peter WL, Xue J, Ebben J, Collins A. Pre-end stage renal disease erythropoietin use predicts hospitalization in the periods before and after end-stage renal disease diagnosis. J Am Soc Nephrol 2001; 12 (Suppl): 1274A (abstract).
57. Collins AJ. Anaemia management prior to dialysis: cardiovascular and cost-benefit observations. Nephrol Dial Transplant 2003; 18 (Suppl 2):ii2-ii6.
58. Xue JL, St Peter WL, Ebben JP, et al. Anemia treatment in the pre-ESRD period and associated mortality in elderly patients. Am J Kidney Dis 2002; 40:1153-1161.
59. Fink JC, Blahut SA, Reddy M, Light PD. Use of erythropoietin before the initiation of dialysis and its impact on mortality. Am J Kidney Dis 2001; 37:348-455.
60. Rossert J, Fouqueray B, Boffa J. Anemia management and the delay of chronic renal failure. J Am Soc Nephrol 2003; 14:S173-S177.
61. Levin A. The relationship of hemoglobin level and survival: direct or indirect effects. Nephrol Dial Transplant 2002; 17 (Suppl 5):8-13.
62. Keane WF, Brenner BM, de Zeeuw D, et al. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL Study. Kidney Int 2003; 63:1499-1507.
63. Mancini DM, Katz SD, Lang C, et al. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 2003; 107:294-299.
64. Mozaffarian D, Nye R, Levy WC. Anemia predicts mortality in severe heart failure. J Am Coll Cardiol 2003; 41:1933-1939.
65. Tang WHW, Miller H, Partin M, et al. Anemia in ambulatory patients with chronic heart failure: a single-center clinical experience derived from electronic medical records. J Am Coll Cardiol 2003; 41 (Suppl A): 157A (Abstract).
66. Bleumink GS, Feenstra J, Sturkenboom MCJM, Sticker BHC. Nonsteroidal anti-inflammatory drugs and heart failure. Drugs 2003; 63:525-534.
67. Bater DC. Anti-inflammatory agents and renal function. Semin Arthritis Rheum 2002; 32:33-42.
68. Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Arch Intern Med 2000; 160:777-784.
69. Maisel AS, Krishnaswamy P, Nowak RN, et al. Breathing Not Properly Multinational Study Investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002; 347:161-167.
70. Wright SP, Doughty RN, Pearl A, et al. Plasma Amino-Terminal Pro-Brain Natriuretic Peptide and accuracy of heart failure diagnosis in primary care. J Amer Coll Cardiol 2003; 42:1793-1800.